Intranasal and intravenous administration of octa-arginine modified poly(lactic-co-glycolic acid) nanoparticles facilitates central nervous system delivery of loperamide

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 4, 2015, Pages 525-536

  O'Donnell, Aisling ^a   Moollan, Azeema ^a   Baneham, Samantha ^a   Ozgul, Melike ^a   Pabari, Ritesh M ^a   Cox, Dermot ^a   Kirby, Brian P ^a   Ramtoola, Zebunnissa ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

central nervous system delivery; loperamide; nanoparticles; octa arginine; PLGA

Indexed keywords

ARGININE; COUMARIN; COUMARIN 6; LOPERAMIDE; NANOPARTICLE; OCTA ARGININE POLY(LACTIC CO GLYCOLIC ACID) NANOPARTICLE; POLYGLACTIN; UNCLASSIFIED DRUG; ANALGESIC AGENT; COUMARIN DERIVATIVE; LACTIC ACID; NANOCONJUGATE; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG LOADING; DRUG RELEASE; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MDCK CELL LINE; MOUSE; NANOANALYSIS; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; DOG; FEMALE; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVENOUS; ANALGESICS; ANIMALS; ARGININE; CELL LINE; CENTRAL NERVOUS SYSTEM; COUMARINS; DOGS; DRUG DELIVERY SYSTEMS; FEMALE; LACTIC ACID; LOPERAMIDE; MALE; MICE, INBRED C57BL; NANOCONJUGATES; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; THIAZOLES;

EID: 84925781252     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12347     Document Type: Article

References (30)

1. Gabathuler R,. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010; 37: 48-57.
2. Stamatovic SM, et al. Brain endothelial cell-cell junctions: how to 'open' the blood brain barrier. Curr Neuropharmacol 2008; 6: 179-192.
3. Brasnjevic I, et al. Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 2009; 87: 212-251.
4. Pardridge WM,. Blood-brain barrier delivery. Drug Discov Today 2007; 12: 54-61.
5. Hombach J, et al. Chitosan solutions and particles: evaluation of their permeation enhancing potential on MDCK cells used as blood brain barrier model. Int J Pharm 2009; 376: 104-109.
6. Li J, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011; 32: 4943-4950.
7. Guo J, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011; 32: 8010-8020.
8. Kanwar JR, et al. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. Nanomedicine 2012; 8: 399-414.
9. Kirby BP, et al. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide. J Pharm Pharmacol 2013; 65: 1473-1481.
10. Rao KS, et al. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008; 29: 4429-4438.
11. Vergoni AV, et al. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine 2009; 5: 369-377.
12. Koch AM, et al. Transport of surface-modified nanoparticles through cell monolayers. Chembiochem 2005; 6: 337-345.
13. Schmidt N, et al. Arginine-rich cell-penetrating peptides. FEBS Lett 2010; 584: 1806-1813.
14. Ziegler A, et al. Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis. Biochemistry 2003; 42: 9185-9194.
15. Dunne M, et al. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 2000; 21: 1659-1668.
16. Ramtoola Z, et al. Investigation of the interaction of biodegradable micro-and nanoparticulate drug delivery systems with platelets. J Pharm Pharmacol 2011; 63: 26-32.
17. BangsLaboratoriesInc. PolyLink Protein Coupling Kit Product data sheet 644. 2010 Product Data Sheet 644, http://search.cosmobio.co.jp/cosmo-search-p/search-gate2/docs/BAN-/PL01N.20070606.pdf.
18. Vega E, et al. Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery. Int J Nanomedicine 2012; 7: 1357-1371.
19. De Rosa R, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005; 102: 3811-3816.
20. Walsh J, et al. Disruption of thermal nociceptive behaviour in mice mutant for the schizophrenia-associated genes NRG1, COMT and DISC1. Brain Res 2010; 1348: 114-119.
21. Siahi-Shadbad MR, et al. Release behaviour of propranolol HCl from hydrophilic matrix tablets containing psyllium powder in combination with hydrophilic polymers. AAPS PharmSciTech 2011; 12: 1176-1182.
22. Chorny M, et al. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release 2002; 83: 389-400.
23. Govender T, et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999; 57: 171-185.
24. Tosi G, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007; 122: 1-9.
25. Vandervoort J, et al. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm 2002; 238: 77-92.
26. Melikov K, et al. Arginine-rich cell penetrating peptides: from endosomal uptake to nuclear delivery. Cell Mol Life Sci 2005; 62: 2739-2749.
27. Richard JP, et al. Cell-penetrating peptides A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003; 278: 585-590.
28. Sahoo SK, et al. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2005; 2: 373-383.
29. Astete CE, et al. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006; 17: 247-289.
30. Privalova A, et al. Intranasal administration: a prospective drug delivery route to the brain. Neurochem J 2012; 6: 77-88.